IL286742A - Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfr - Google Patents
Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfrInfo
- Publication number
- IL286742A IL286742A IL286742A IL28674221A IL286742A IL 286742 A IL286742 A IL 286742A IL 286742 A IL286742 A IL 286742A IL 28674221 A IL28674221 A IL 28674221A IL 286742 A IL286742 A IL 286742A
- Authority
- IL
- Israel
- Prior art keywords
- insertions
- compounds
- cancer cells
- activity against
- tumor activity
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 108060006698 EGF receptor Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000003780 insertion Methods 0.000 title 1
- 230000037431 insertion Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826843P | 2019-03-29 | 2019-03-29 | |
| PCT/US2020/025228 WO2020205521A1 (en) | 2019-03-29 | 2020-03-27 | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL286742A true IL286742A (en) | 2021-10-31 |
Family
ID=72666976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL286742A IL286742A (en) | 2019-03-29 | 2021-09-27 | Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfr |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220143023A1 (https=) |
| EP (1) | EP3946293A4 (https=) |
| JP (2) | JP7650814B2 (https=) |
| KR (1) | KR20210149103A (https=) |
| CN (1) | CN113939284A (https=) |
| AU (1) | AU2020254499A1 (https=) |
| BR (1) | BR112021019489A2 (https=) |
| CA (1) | CA3131864A1 (https=) |
| IL (1) | IL286742A (https=) |
| MX (1) | MX2021011948A (https=) |
| PH (1) | PH12021552395A1 (https=) |
| SG (1) | SG11202110669WA (https=) |
| WO (1) | WO2020205521A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110129434A (zh) * | 2018-02-08 | 2019-08-16 | 埃提斯生物技术（上海）有限公司 | 胆汁中生物标志物在诊断恶性肿瘤中的应用 |
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| MX2021011948A (es) * | 2019-03-29 | 2022-01-04 | Univ Texas | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. |
| EP3956035A4 (en) * | 2019-04-17 | 2023-01-25 | Board of Regents, The University of Texas System | ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| JP7783182B2 (ja) | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| PY21113397A (es) * | 2020-12-29 | 2022-10-12 | Spectrum Pharmaceuticals Inc | Tratamiento para tumores sólidos malignos |
| WO2022206929A1 (zh) * | 2021-04-01 | 2022-10-06 | 上海医药集团股份有限公司 | 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 |
| WO2023015149A1 (en) * | 2021-08-02 | 2023-02-09 | Spectrum Pharmaceuticals, Inc. | Treatment of non-small cell lung cancer with poziotinib |
| KR20230063731A (ko) | 2021-11-02 | 2023-05-09 | 주식회사 엘지에너지솔루션 | 전해액의 분할 주입을 포함하는 이차전지의 제조방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10308658B2 (en) * | 2015-10-19 | 2019-06-04 | Sunshine Lake Pharma Co., Ltd. | Salt of EGFR inhibitor, crystalline form and uses thereof |
| KR102771603B1 (ko) * | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| EP3687542A1 (en) * | 2017-09-27 | 2020-08-05 | AI Therapeutics, Inc. | Therapeutic methods relating to hsp90 inhibitors |
| WO2019178239A1 (en) * | 2018-03-13 | 2019-09-19 | Board Of Regents, The University Of Texas System | Methods for treatment of cancers with egfr activating mutations |
| AU2019243738B2 (en) * | 2018-03-27 | 2024-05-30 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations |
| MX2021011948A (es) * | 2019-03-29 | 2022-01-04 | Univ Texas | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. |
-
2020
- 2020-03-27 MX MX2021011948A patent/MX2021011948A/es unknown
- 2020-03-27 US US17/599,969 patent/US20220143023A1/en not_active Abandoned
- 2020-03-27 AU AU2020254499A patent/AU2020254499A1/en not_active Abandoned
- 2020-03-27 CN CN202080038791.0A patent/CN113939284A/zh active Pending
- 2020-03-27 WO PCT/US2020/025228 patent/WO2020205521A1/en not_active Ceased
- 2020-03-27 PH PH1/2021/552395A patent/PH12021552395A1/en unknown
- 2020-03-27 CA CA3131864A patent/CA3131864A1/en active Pending
- 2020-03-27 KR KR1020217035240A patent/KR20210149103A/ko active Pending
- 2020-03-27 JP JP2021557927A patent/JP7650814B2/ja active Active
- 2020-03-27 BR BR112021019489A patent/BR112021019489A2/pt not_active Application Discontinuation
- 2020-03-27 EP EP20783802.0A patent/EP3946293A4/en active Pending
- 2020-03-27 SG SG11202110669WA patent/SG11202110669WA/en unknown
-
2021
- 2021-09-27 IL IL286742A patent/IL286742A/en unknown
-
2025
- 2025-03-12 JP JP2025038928A patent/JP2025090740A/ja active Pending
- 2025-04-01 US US19/097,461 patent/US20250312348A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022527788A (ja) | 2022-06-06 |
| JP7650814B2 (ja) | 2025-03-25 |
| US20220143023A1 (en) | 2022-05-12 |
| US20250312348A1 (en) | 2025-10-09 |
| EP3946293A4 (en) | 2023-05-03 |
| MX2021011948A (es) | 2022-01-04 |
| EP3946293A1 (en) | 2022-02-09 |
| KR20210149103A (ko) | 2021-12-08 |
| SG11202110669WA (en) | 2021-10-28 |
| CN113939284A (zh) | 2022-01-14 |
| JP2025090740A (ja) | 2025-06-17 |
| BR112021019489A2 (pt) | 2022-02-08 |
| CA3131864A1 (en) | 2020-10-08 |
| WO2020205521A1 (en) | 2020-10-08 |
| PH12021552395A1 (en) | 2022-06-13 |
| AU2020254499A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286742A (en) | Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfr | |
| IL286576A (en) | Compounds with antitumor activity against cancer cells containing exon 21 her2 insertions | |
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| SG11202106435QA (en) | Treating gastric cancer using ttfields combined with xelox or folfox | |
| MX2024000253A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| JOP20190154A1 (ar) | بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم | |
| MX385562B (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2. | |
| MX393599B (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco | |
| IL277373A (en) | Compounds with antitumor activity against cancer cells with a mutation in exon 19 of HER2 | |
| MX390435B (es) | Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20. | |
| PH12021552579A1 (en) | Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations | |
| EP4031224A4 (en) | MANDRIN WITH IMPROVED THREADABILITY | |
| MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. | |
| IL276235B2 (en) | Use of Minfrain to reduce tumor growth | |
| EP3303363A4 (en) | INTRAPATIENT GENOMHETEROGENICITY OF INDIVIDUAL CIRCULATIVE TUMOR CELLS (CTCS) RELATED TO PHENOTYPIC CTC HETEROGENICITY IN METASTASED, CASTING RESISTANT PROSTATE CANCER (MCRPC) | |
| IL292049A (en) | Combination therapy for cancer with kras mutation | |
| GB201918313D0 (en) | Cells for treating cancer | |
| MX2009010954A (es) | Actividad antitumoral de temsirolimus en cancer celular renal papilar. | |
| WO2015057737A3 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS | |
| GB2580123B (en) | Raising roof assemblies | |
| IL316821A (en) | Cancer treatment with NUC-7738 | |
| HK40076174A (en) | Cells for treating cancer | |
| WO2014153464A3 (en) | 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer | |
| HK40101495A (en) | Combination therapy with for46 for cancer | |
| HK40068399A (en) | Osimertinib for use in the treatment of non-small cell lung cancer |